|
US2016317491A1
|
|
Artificial tears solution combination
|
|
US2017258896A1
|
|
Endotoxin nanovesicles: hydrophilic gold nanodots control lipopolysaccharide assembly for modulating immunological responses
|
|
TW201625526A
|
|
5-methoxytryptophan and its derivatives and uses thereof
|
|
TW201718846A
|
|
Device and method for single cell isolation and cultivation
|
|
WO2016044421A1
|
|
Progenitor cells, method for preparation thereof and uses thereof
|
|
WO2016043937A1
|
|
Methods to upregulate and suppress an expression of immunomodulatory cells
|
|
SG11201700971XA
|
|
Methods to enhance nerve regeneration utilizing neural stem cells and il12p40
|
|
CN106661102A
|
|
Viral particles as immunogens against enterovirus infection and production thereof
|
|
US2015336976A1
|
|
Dipicolylamine derivatives and their pharmaceutical uses
|
|
TW201637652A
|
|
Artificial tear composition
|
|
KR20170068410A
|
|
Adenoviral vector-based vaccine against enterovirus infection
|
|
WO2016093823A1
|
|
Antibodies and method for determining deletions in hbv pre-s2 region
|
|
TW201617365A
|
|
Antibodies and method for determining deletions in hbv pre-s2 region
|
|
US2015072885A1
|
|
Antibodies and method for determining deletions in HBV pre-S2 region
|
|
EP2997181A1
|
|
Methods of prognostically classifying and treating glandular cancers
|
|
US2014271700A1
|
|
Compositions and methods for treating clostridium difficile-associated diseases
|
|
WO2014082055A2
|
|
Primers, snp markers and method for genotyping mycobacterium tuberculosis
|
|
CN105228619A
|
|
The medical composition that treatment hepatitis C virus infects
|
|
TW201434509A
|
|
System for destroying adipose tissue non-invasively and accelerating lipid metabolism
|
|
CN104781395A
|
|
Method for generating immunomodulatory cells, cells prepared therefrom, and use thereof
|
